Skip to main content
Fig. 17 | BMC Cancer

Fig. 17

From: Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer

Fig. 17

Forest Plot of SAEs: Safety Analysis. Estimates derived only from indirect comparisons shown in black box. Included references: Study 301 (Kaufman 2015, Pivot 2018), EMBRACE (Cortes 2011), Zhang 2017. Abbreviations: CAP = capecitabine; CrI = credible interval; ERI = eribulin; SAE = serious adverse event; TPC = treatment by physician’s choice; UTI = utidelone

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us